spac
spacmenufooter
spacer
spacKontaktspacSo finden Sie unsspacKlinikumseinrichtungenspacPresse
Google-Suchmaschine
Gesamte Uniklinikseite
Interne Suchmaschine
Zentrale Uniklinikseite
Interne Suchmaschine
Aktuelle Uniklinikseite (anaesthesie)
Suche nach Stichworten
Begriffe, Krankheiten, Einrichtungen u.v.m., verknüpft mit dem zuständigen Bereich.
Personensuche
Nachname:
Vorname:
Org.-Einheit:
Modus: gleich Suchmuster
enthält Suchmuster
phonetische Suche
Suche nach Einrichtungen:
Such-Bereich:Klinikum
Bezeichnung:
Modus: gleich Suchmuster
enthält Suchmuster
phonetische Suche
Suche über die Einrichtungen
Im Menüpunkt "Übersicht" sind Einrichtungen unter verschiedenen Gesichtspunkten gruppiert: Kliniken, Abteilungen, Institute, Zentrale Einrichtungen und ähnliches.
Smart-Link
Seitenaufruf mit Smart-Link--> Info hier!
smartlink-symbol

spacer
spacer
spac

Prof. Dr. Heike L. Pahl

Publikationen / Publications                                                                                      zurück >

Hämatologie / Haematology

  1. Kaufmann KB, Gründer A, Hadlich T, Wehrle J, Gothwal M, Bogeska R, Seeger TS, Kayer S, Pham KB, Jutzi JS, Ganzenmüller L, Steinemann D, Schlegelberger B, Wagner JM, Jung M, Will B, Steidl U, Aumann K, Werner M, Günther T, Schüle R, Rambaldi A, Pahl HL , (2011) Overexpression of transcription factor NF-E2: a novel murine model of myeloproliferative neoplasms, J. Exp. Med, in press.
  2. Kroeze LI, Nikoloski G, da Silva-Coelho P, van Hoogen P, Stevens-Linders E, Kuiper RP, Schnittger S, Haferlach T, Pahl HL , van der Reijden BA, Jansen JH (2011) Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies., Blood, in press.
  3. Fleischman AG, Aichberger KJ, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Loriaux MM, Pahl HL , Silver RT, Agarwal A, O’Hare T, Druker BJ, Bagby CG, Deininger MW (2011) Tumor necrosis factor-alpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms, Blood, in press.
  4. Duque-Afonso J, Solari L, Essig A, Berg T, Pahl HL , Lübbert M. (2011) Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiation. British J. Haematol, 153:612 – 622.
  5. Wang W, Schwemmers S, Hexner EO, Pahl HL (2010) AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood, 116: 254 - 266. (PDF-file)
  6. Roelz R, Pilz IH, Mutschler M, Pahl HL (2010) Of Mice and Men: Human RNA Polymerase III Promoter U6 is more efficient than its murine homologue for shRNA Expression from a Lentiviral Vector in both Human and Murine Progenitor Cells. Exp. Hematol., in press. (PDF-file)
  7. Mutschler M, Magin AS, Buerge M, Roelz R, Schanne DH, Will B, Pilz I, Migliaccio AR, Pahl HL (2009) NF-E2 Overexpression Delays Erythroid Maturation and Increases Erythrocyte Production, British J. Haematol., 146: 203 - 217. (PDF-file)
  8. Cario H, McMullin MF, Pahl HL (2009) Clinical and hematological presentation of children and adolescents with polycythemia vera, Ann. Hematol., 88: 713 - 719. (PDF-file)
  9. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Reiter A, Grand F, Cross NCP (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms, Nature Genetics, 41: 446 – 449. (PDF-file)
  10. Cario H, Schwarz K, Herter JM, Komrska V, McMullin MF, Minkov M, Niemeyer C, Pospisilova D, Reinhard H, Debatin KM, Pahl HL (2008) Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera. Br. J. Haematol., 142: 622-626. (PDF-file)
  11. Huai J, Firat E, Nil A, Million D, Gaedicke S, Kanzler B, Freudenberg M, van Endert P, Kohler G, Pahl HL, Aichele P, Eichmann K, Niedermann G (2008) Activation of cellular death programs associated with immunosenescence-like phenotype in TPPII knockout mice. PNAS, 105: 5177 – 5182. (PDF-file)
  12. Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B, Pahl HL (2007) JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. Exp Hematol, 35 (11): 1695 - 1703   (PDF-file)
  13. Rives S, Pahl HL, Florensa L, Bellosillo B, Neusuess A, Estella J, Debatin KM, Kohne E, Schwarz K, Cario H (2007) Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis. Haematologica/The Hematology Journal, 92: 674 - 677   (PDF-file)
  14. El-Moneim AA, Kratz CP, Boell S, Rister M, Pahl HL, Niemeyer CM (2007) Essential versus reactive thrombocythemia in children: Retrospective analyses of 12 cases.Pediatr Blood Cancer, 49: 52 - 56   (PDF-file)
  15. Steimle C, Lehmann U, Temerinac S, Goerttler PS, Kreipe H, Meinhardt G, Heimpel H, Pahl HL (2007) Biomarker analysis in Polycythemia vera under interferon-alpha treatment: Clonality, EEC, PRV-1 and JAK2 V617F. Ann. Hematol, 86 (4): 239 - 244   (PDF-file)
  16. Samuelsson J, Mutschler M, Birgegard G, Hansen PG, Bjorkholm M, Pahl HL (2006) Limited Effects on JAK2 Mutational Status after Pegylated Interferon α-2b Therapy in Polycythemia vera and Essential Thrombocythemia. Haematologica/The Hematology Journal, 91 (9): 1281-1282. (PDF-file)
  17. Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M, Linder O, Bjorkholm M, Pahl HL, Birgegard G, and the Nordic study group for myeloproliferative disorders (NMPD). (2006) A Phase II Trial of Pegylated Interferon α-2b Therapy in Polycythemia vera and Essential Thrombocythemia. Feasibility, Clinical and Biological Effects and Impact on Quality of Life. Cancer, 106: 2397-2405 (PDF-file)
  18. Bench AJ, Pahl HL (2005) Chromosomal Abnormalities and Molecular Markers in Myeloproliferative Disorders. Semin. Hematol., 42: 196-205. (PDF-file)
  19. Langer C, Lengfelder E, Thiele J, Kvasnicka HM, Pahl HL, Stade B, Beneke H, Schauer S, Gisslinger H, Griesshammer M (2005) Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica/The Hematology Journal,  90:1333-1338. (PDF-file)
  20. Cario H, Steimle C, Goerttler PS, Levine RL, Pahl HL (2005) The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial Polycythaemia vera, Br. J. Hematol, 130: 800-801. 
  21. Goerttler PS, Steimle C, März E, Johansson PL, Andreasson B, Griesshammer M, Gisslinger H, Heimpel H, Pahl HL (2005) The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood, 106: 2862-2864.  
  22. Goerttler PS, März E, Johansson PL, Andreasson B, Kutti J, Moliterno AR, Marchioli R, Spivak JL, Pahl HL for the MPD Research Consortium (2005) Thrombotic and Bleeding Complications in Four Subpopulations of Patients with ET Defined by c-Mpl Protein Expression and PRV-1 mRNA Levels. Haematologica/The Hematology Journal, 90:851-853. (PDF-file)
  23. Goerttler PS, Kreutz C, Donauer J, Faller D, Maiwald T, März E, Rumberger B, Sparna T, Schmitt-Gräff A, Wilpert J, Timmer J, Walz G, Pahl HL (2005) Gene Expression Profiling in Polycythemia vera: Overexpression of transcription factor NF-E2., Br. J. Haematol, 129: 138-150. (PDF-file)
  24. Pahl HL (2004) Current Evaluation of the Clinical, Diagnostic, and Therapeutic Usefulness of prv-1 and c-mpl Markers in Polycythemia Vera and Essential Thrombocythemia. Clin Adv Hematol Oncol, 2: 202-204. (PDF-file)
  25. Pahl HL (2004) Diagnostic Approaches to Polycythemia vera in 2004. Exp. Rev. Mol. Diagn. 4: 495-501.
  26. Palmqvist L, Goerttler P, Wasslavik C, Johansson P, Andreasson B, Safai-Kutti S, Kutti J, Pahl HL, Ricksten A (2004) Method comparison of PRV-1 mRNA quantification in whole blood leukocytes and purified granulocytes., Clin. Chem., 50: 644-647. (PDF-file)
  27. Klippel S, Pahl HL (2004) Molecular Markers for the Diagnosis of Philadelphia Chromosome Negative Myeloproliferative Disorders, Pathol. Biol., 52: 267-274.
  28. Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U, Heimpel H, Pahl HL (2004) PRV-1 mRNA expression discriminates two types of Essential Thrombocythemia., Ann. Hematol., 83: 364-370. (PDF-file)
  29. Klippel S, Strunck E, Temerinac S, Meinhardt G, Mohr U, Leichtle R, Griesshammer M, Heimpel H, Pahl HL (2003) Quantification of PRV-1 mRNA distinguishes Polycythemia vera from Secondary Erythrocytosis., Blood, 102: 3569-3574. (PDF-file)
  30. Cario H, Pahl HL, Schwarz K, Galm C, Hoffmann M, Burdelski M, Kohne E, Debatin KM (2003) Familial Polycythemia vera with Budd-Chiari-Syndrome in childhood. Case report and review of the literature., Br. J. Hematol, 123: 346-349. (PDF-file)
  31. Pahl HL (2003) Molecular Markers in Myeloproliferative Disorders: From Classification to Prognosis? Hematology, 8: 199-209.
  32. Pahl HL (2003) PRV-1 and other Molecular Markers in Myeloproliferative Disorders, Curr. Hematol. Rep., 2:231-236.
  33. Loop T, Pahl HL (2003) Activators and Targets of the Transcription Factor NF-κB: From Bench to Bedside., In: Nuclear Factor κB, R. Beyaert ed. Kluwer, Dordrecht. Pp.: 1-49.
  34. Klippel S, Strunck E , Busse CE, Behringer D, Pahl HL (2002) Biochemical Characterization of PRV-1, a Novel Hematopoietic Cell Surface Receptor, which is Overexpressed in Polycythemia rubra vera., Blood, 100: 2441-2448. (PDF-file)
  35. Pahl HL (2002) Polycythaemia vera: Will new markers help us answer old questions? Acta Haematol., 108:120-131.
  36. Knorre A, Wagner M, Schaefer HE, Colledge WH, Pahl HL (2002) ΔF508-CFTR causes constitutive NF-κB activation through an ER-Overload Response in Cystic Fibrosis lungs. Biol. Chem., 383:271-282.
  37. Klaas CA, Wagner G, Laufer S, Sosa S, Della Loggia R, Bomme U, Pahl HL, Merfort I (2002) Studies on the anti-Inflammatory activity of phytopharmaceuticals prepared from Arnica flowers. Planta Med. 68:385-391.
  38. Garcia-Pineres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Merfort I*, Pahl HL* (2001) Sesquiterpene lactones inhibit the transcription factor NF-κB by alkylating its p65 subunit. J. Biol. Chem, 276:39713-39720. *: both authors contributed equally to the work and are listed in reverse order on the publication.
  39. Röder S, Meinhardt G, Pahl HL (2001) STAT3 is constitutively active in some patients with Polycythemia vera. Exp. Hematol., 29:694-702.
  40. Pahl HL (2000) Towards a molecular understanding of Polycythemia rubra vera. Eur. J. Biochem., 267: 3395-3401.
  41. Temerinac S, Klippel S, Röder S, Lübbert M, Lange W, Azemar M, Meinhardt G, Pahl HL (2000) Cloning of PRV-1, a Novel Member of the uPAR Receptor Superfamily, which is Overexpressed in Polycythemia rubra vera. Blood, 95: 2569-2576. (PDF-file)
  42. Meyer-ter-Vehn T, Covacci A, Kist M, Pahl HL (2000) Helicobacter pylori activates MAP Kinase cascades and induces expression of the proto-oncogenes c-fos and c-jun. J. Biol. Chem., 275: 16064-16072.
  43. Castro V, Murillo R, Klaas C, Meunier C, Mora G, Pahl HL, Merfort I (2000) Sesquiterpene lactones from Podachaenium eminens possess anti-inflammatory activity. Planta Med., 66:591-595.
  44. Lyß G, Glasl S, Jurenitsch J, Pahl HL, Merfort I (2000) A sesquiterpene and sesquiterpene lactones from the Achillea millefolium group possess antiinflammatory properties but do not inhibit the transcription factor NF-κB. Pharm. Pharmacol. Lett., 10: 13-15.
  45. Müller J, Pahl HL (2000) Assaying NF-kappaB and AP-1 DNA-binding and transcriptional activity. Methods Mol. Biol., 99: 205-215.
  46. Castro V, Rüngeler P, Murillo R, Hernandez E, Mora G, Pahl HL, Merfort I (2000) Study of sesquiterpene lactones from Milleria quinqueflora on their anti-inflammatory activity using the transcription factor NF-κB as a molecular target. Phytochemistry, 53: 257-263
  47. Schmidt TJ, Lyß G, Pahl HL, Merfort I (1999) Helenanolide type sesquiterpene lactones-V. The role of glutathione addition under physiological conditions. Bioorg. Med. Chem., 7: 2849-2855
  48. Zidorn C, Dirsch VM, Rüngeler P, Sosa S, Della Loggia R, Merfort I, Pahl HL, Vollmar AM, Stuppner H (1999) Antiinflammatory activities of hypocretenolides from Leontodon hispidus. Planta Med. 65: 704-708
  49. Rüngeler P, Castro V, Mora G, Gören N, Vichnewski W, Pahl HL, Merfort I, Schmidt TJ (1999) Inhibition of transcription factor NF-κB by sesquiterpene lactones – a proposed molecular mechanism of action. Bioorg. Med. Chem., 7: 2343-2352
  50. Pahl HL (1999) Activators and Target Genes of NF-κB. Oncogene Reviews, 18: 6853-6866
  51. Lyß G, Schmidt TJ, Pahl HL, Merfort I (1999) Studies of the anti-inflammatory activity of Arnica tincture using the transcription factor NF-κB as a molecular target. Pharm. Pharmacol. Lett., 9: 5–8
  52. Pahl HL (1999) Signal transduction from the endoplasmic reticulum to the cell nucleus. Physiol. Rev., 79: 683-701
  53. v. Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC (1999) CD40 ligation augments CTL mediated lysis and induces apoptosis in human malignant melanoma. Cancer Res., 59: 1287-1294.
  54. Sembries S, Pahl HL, Stilgenbauer S, Döhner H, Schriever F (1999) Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion. Blood, 93: 624-631. (PDF-file)
  55. Lyß G, Knorre A, Schmidt TJ, Merfort I*, Pahl HL* (1998) The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-κB by directly targeting p65. J. Biol. Chem., 273: 33508-33516. *: both authors contributed equally to the work and are listed in reverse order on the publication.
  56. Rüngeler P, Lyß G, Castro V, Mora G, Pahl HL, Merfort M (1998)Pharmacological studies of three sesquiterpene lactones from Tithonia diversifolia. Plant. Med., 64: 587-682.
  57. Burns K, Martinon F, Esslinger C, Pahl HL, Schneider P, Bodmer J-L, Di Marco F, French L, Tschopp J (1998) MyD88, an adapter protein involved in Interleukin-1 Signaling. J. Biol. Chem. 273: 12203-12209.
  58. Glocker E, Lange C, Covacci A, Bereswill S, Kist M, Pahl HL (1998) Proteins encoded by the cag pathogenicity island of Helicobacter pylori are required for NF-κB activation. Infect. Immun., 66: 2346-2348.
  59. Münzenmaier A, Lange C, Covacci A, Moran A, Bereswill S, Baeuerle PA, Kist M, Pahl HL (1997) A secreted product of Helicobacter pylori activates transcription factor NF-κB. J. Immunol., 159: 6140- 6147.
  60. Lyß G, Willuhn G, Merfort I, Pahl HL (1997) The anti-inflammatory sesquiterpene lactone helenalin specifically inhibits transcription factor NF-κB. Biol. Chem., 378: 951-961.
  61. Pahl HL, Baeuerle PA (1997) The ER Overload Response: Activation of NF-κB. Trends in Biochem. Sci., 22: 63-67.
  62. Pahl HL, Baeuerle PA (1997) Endoplasmic Reticulum-Induced Signal Transduction and Gene Expression. Trends Cell Biol., 7: 50-55.
  63. Schadendorf D, Kern MA, Artuc M, Pahl HL, Rosenbach T , Fichtner I, Nürnberg W, Stüting S, v. Stebut E, Worm M, Makki A, Jurgovsky K, Kolde G, Henz BM (1996) Treatment of Melanoma Cells with the synthetic Retinoid CD 437 induces Apoptosis via Activation of AP-1 in vitro, and causes Growth Inhibition in Xenografts in vivo. J. Cell. Biol., 135: 1889-1898.
  64. Pahl HL, Baeuerle PA (1996) Activation of NF-κB by ER stress requires both Ca2+ and reactive oxygen intermediates as messengers. FEBS Lett. 392: 129-136.
  65. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB-M, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA, Peyron J-F (1996) Tyrosine phosphorylation of IκB-α activates NF-κB without proteolytic degradation of IκB-α.Cell 86 : 787-798.
  66. Pahl HL and Baeuerle PA (1996) Gene Control by Proteolysis. Curr. Opin. Cell Biol. 8: 340-347.
  67. Pahl HL, Krauß B, Schulze-Osthoff K, Decker T, Traenckner EB-M, Myers C, Parks T, Warring P, Czernilofsky AP and Baeuerle PA. (1996) The Immunosuppressive Fungal Metabolite Gliotoxin Specifically Inhibits Transcription Factor NF-κB. J. Exp. Med., 183:1829-1840.
  68. Pahl HL, Sester M, Burgert, H-G and Baeuerle PA. (1996) Activation of Transcription Factor NF-B by the Adenovirus E3/19K Protein Requires its ER Retention. J. Cell. Biol. 1 32:511-522.
  69. Baeuerle PA, Rupec RA and Pahl HL. (1996) Reactive oxygen intermediates as second messengers of a general pathogen response. Path. Biol. 4 4:29-35.
  70. Pahl HL and Baeuerle PA. (1996) Strategies to identify transcription factors and their target genes. in Methods in Molecular Genetics, (K. W. Adolph, Ed.) pp. 278-297, Academic Press.
  71. Treanckner EB-M, Pahl HL, Henkel T, Schmidt KN, Wilk S, and Baeuerle PA. (1995) Phosphorylation of human IκB-α on serine 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J. 14:2876-2883.
  72. Pahl HL and Baeuerle PA. (1995) A novel signal transduction pathway between the endoplasmic reticulum and the nucleus is mediated by transcription factor NF-κB. EMBO J. 14:2580-2588.
  73. Pahl HL and Baeuerle PA. (1995) Expression of influenza virus hemagglutinin activates transcription factor NF-κB. J. Virol. 69:1480-1484.
  74. Dziennis S, Van Etten, RA, Pahl HL, Morris DL, Rothstein TL, Blosch CM, Perlmutter RM, Tenen DG. (1995) The CD11b promoter directs high-level expression of reporter genes in macrophages in transgenic mice. Blood 85:319-329.
  75. Meyer M, Pahl HL, Baeuerle PA. (1994) Regulation of the transcription factors NF-κB and AP-1 by redox changes. Chem.-Biol. Interact. 91:91-100.
  76. Pahl HL, Baeuerle PA. (1994) Oxygen and the control of gene expression. BioEssays 16:497-502.
  77. Pahl HL*, Flemming JE*, Gonzalez DA, Smith TF, Tenen DG. (1993) Structural analysis of the CD11b gene and phylogenetic analysis of the alpha integrin gene family demonstrate remarkable conservation of genomic organization and suggest early diversification during evolution. J. Immunol. 150:480-490. *: both authors contributed equally to the work and are listed in alphabetical order on the publication.
  78. Pahl HL*, Chen H-M*, Zhang D-E, Tenen DG. (1993) The Sp1 transcription factor binds the CD11b promoter specifically in myeloid cells in vivo and is essential for myeloid specific promoter activity. J. Biol. Chem. 268:8230-8239.
  79. Pahl HL, Scheibe RJ, Chen H-M, Zhang D-E, Galson DL, Maki RA, Tenen DG. (1993) The proto-oncogene PU.1 regulates expression of the myeloid specific CD11b promoter. J. Biol. Chem. 268:5014-5020.
  80. Pahl HL, Rosmarin AG, Tenen DG. (1992) Characterization of the myeloid specific CD11b promoter. Blood 79:865-870.
  81. Pahl HL, Burn TC, Tenen DG. (1991) Optimization of transient transfection into human myeloid cell lines using a luciferase reporter gene. Exp. Hematol. 19:1038-1041.

Anästhesiologie / Anesthesia

  1. Schallner N, Schwemmers S, Schwer CI, Froehlich C, Stoll P, Humar M, Pahl HL, Hoetzel A, Loop T, Goebel U (2011) p38β-regulated induction of the heat shock response by carbon monoxide releasing molecule CORM-2 mediates cytoprotection in lung cells in vitro. Eur. J. Pharmacol., 670:58-66.
  2. Goebel U, Mecklenburg A, Siepe M, Roesslein M, Schwer CI, Pahl HL, Priebe HJ, Schlensak C, Loop T (2009) Protective effects of inhaled carbon monoxide in pig lungs during cardiopulmonary bypass are mediated via an induction of the heat shock response. Br J Anaesth., 103: 173-184.
  3. Helbing T, Volkmar F, Goebel U, Heinke J, Diehl P, Pahl HL, Bode C, Patterson C, Moser M (2009) Krüppel-like factor 15 regulates BMPER in endothelial cells. Cardiovasc Res., 85: 551-559.
  4. Cario H, McMullin MF, Pahl HL (2009) Clinical and hematological presentation of children and adolescents with polycythemia vera, Ann. Hematol., 88: 713 - 719.
  5. Humar M, Dohrmann H, Stein P, Andriopoulos N, Goebel U, Roesslein M, Schmidt R, Schwer CI, Loop T, Geiger KK, Pahl HL, Pannen BH  (2008)Thionamides inhibit the transcription factor NF-κB by suppression of the small GTPase Rac1 and IKKα. J Pharmacol Exp Ther; 324: 1037-44. (PDF-file)
  6. Roesslein M, Schibilsky D, Muller L, Goebel U, Schwer C, Humar M, Schmidt R, Geiger KK, Pahl HL, Pannen BHJ, Loop T (2008) Thiopental protects human T lymphocytes from apoptosis in vitro via the expression of heat shock protein 70. J Pharmacol Exp Ther; 325: 217-25. (PDF-file)
  7. Roesslein M, Frick M, Auwaerter V, Humar M, Goebel U, Schwer C, Geiger KK, Pahl H, Pannen BHJ, Loop T (2008) Sevoflurane-mediated activation of p38-mitogen-activated stresskinase is independent of apoptosis in Jurkat T-cells. Anesth Analg; 106: 1150-60. (PDF-file)
  8. Goebel U, Siepe M, Mecklenburg A, Stein P, Roesslein M, Schwer C, Schmidt R, Doenst T, Geiger KK, Pahl HL, Schlensak C, Loop T (2008) Carbon Monoxide Inhalation Reduces Pulmonary Inflammatory Response during Cardiopulmonary Bypass in Pigs. Anesthesiology, 108 (6): 1025-36. (PDF-file)
  9. Humar M, Dohrmann H, Stein P, Andriopoulos N, Goebel U, Heimrich B, Roesslein M, Schmidt R, Schwer CI, Hoetzel A, Loop T, Pahl HL, Geiger KK, Pannen BH (2007) Repression of T-cell function by thionamides is mediated by inhibition of the activator protein-1/nuclear factor of activated T-cells pathway and is associated with a common structure. Mol Pharmacol., 72: 1647-56. (PDF-file)
  10. Humar M, Loop T, Schmidt R, Hoetzel A, Roesslein M, Andriopoulos N, Pahl HL, Geiger KK, Pannen BH (2007) The mitogen-activated protein kinase p38 regulates activator protein 1 by direct phosphorylation of c-Jun. Int J Biochem Cell Biol., 39: 2278-88  
  11. Loop T, Doviakue D, Frick M, Roesslein M, Egger L, Musshoff F, Humar M, Hoetzel A, Schmidt R, Borner C, Geiger KK, Pahl HL, Pannen BHJ (2005) Volatile anesthetics induce caspase-dependent, mitochondria-mediated apoptosis in human T lymphocytes in vitro. Anesthesiology, 102: 1147-1157.(PDF-file)
  12. Kirchner EA, Mols G, Muehlschlefel JD, Geiger KK, Guttmann J, Pahl HL (2005) Dynamic compliance based PEEP adjustment reduces activation of NF-kappaB and AP-1 in isolated perfused rabbit lungs during low tidal volume vintilation., Br. J Anaesth, 34: 530-534.
  13. Loop T, Bross T, Humar M, Hoetzel A, Schmidt R, Pahl HL, Geiger KK, Pannen BHJ (2004) Dobutamine inhibits Phorbol-Myristate-Acetate (PMA)-induced activation of nuclear factor κB in human T lymphocytes in vitro. Anesth. Analg., 99: 1508-1515. (PDF-file)
  14. Loop T, Scheiermann P, Doviakue D, Musshoff F, Humar M, Roesslein M, Hoetzel A, Schmidt R, Borner C, Geiger KK, Pahl HL, Pannen BHJ (2004) Sevoflurane inhibits phorbol-myristate-acetate-induced Activator Protein-1 activation in human T lymphocytes in vitro: Potential role of the p38-stress kinase pathway. Anesthesiology, 101: 710-721. (PDF-file)
  15. Schmidt R, Hoetzel A, Baechle T, Loop T, Humar M, Bauer M, Pahl HL, Geiger KK, Pannen BHJ (2004) Isoflurane pretreatment lowers portal venous resistance by increasing hepatic heme oxygenase activity in the rat liver in vivo. J. Hepatol., 41: 706-713. (PDF-file)
  16. Humar M, Andriopoulos N, Pischke SE, Loop T, Schmidt R, Hoetzel A, Roesslein M, Pahl HL, Geiger KK, Pannen BJHJ (2004) Inhibition of AP-1 by barbiturates is mediated by differential effects on MAP-kinases and the small G proteins Ras and Rac-1. J. Pharmacol. Exp. Ther., 311: 1232-1240. (PDF-file)
  17. Humar M, Pieschke S, Loop T, Hoetzel A, Schmidt R, Klaas C, Pahl HL, Geiger KK, Pannen BHJ (2004) Barbiturates directly inhibit the calmodulin/calcineurin complex: a novel mechanism of inhibition of nuclear factor of activated T cells., Mol. Pharmacol. 65: 350-361. (PDF-file)
  18. Loop T, Humar M, Pischke S, Hoetzel A, Schmidt R, Pahl HL, Geiger KK, Pannen BHJ (2003) Thiopental inhibits TNF-α-induced activation of Nuclear Factor-κB through suppression of IκB Kinase activity. Anaesthiology, 99: 360-367.
  19. Hoetzel A, Geiger S, Loop T, Welle A, Schmidt R, Humar M, Pahl HL, Geiger KK, Pannen BHJ (2002) Differential Effects of Volatile Anesthetics on Hepatic Heme Oxygenase-1 Expression in the Rat. Anaesthesiology, 97: 1318-1321.
  20. Loop T, Liu Z, Humar M, Hoetzel A, Benzing A, Pahl HL, Geiger KK, Pannen BHJ (2002) Thiopental inhibits the activation of Nuclear Factor-κB, Anaesthesiology, 96:1202-1213.
  21. Hoetzel A, Vagts D, Loop T, Humar M, Bauer M, Pahl HL, Geiger KK, Pannen BHJ (2001) The effect of nitric oxide on shock-induced hepatic hemeoxigenase-1 expression in the rat. Hepatology, 33:925-937.

                                                                                                                                  zurück >